Lance Alstodt - Nov 3, 2022 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
President, CEO, COB, Director
Signature
/s/ Lance Alstodt
Stock symbol
BRTX
Transactions as of
Nov 3, 2022
Transactions value $
$0
Form type
4
Date filed
11/4/2022, 04:16 PM
Previous filing
Sep 23, 2022
Next filing
Nov 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BRTX Common Stock 183K Nov 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BRTX Stock Option Disposed to Issuer $0 -293K -100% $0.00* 0 Nov 3, 2022 Common Stock 293K $13.50 Direct F2, F4
transaction BRTX Stock Option Award $0 +293K $0.00 293K Nov 3, 2022 Common Stock 293K $5.08 Direct F2, F4
transaction BRTX Stock Option Disposed to Issuer $0 -42.1K -100% $0.00* 0 Nov 3, 2022 Common Stock 42.1K $13.50 Direct F3, F4
transaction BRTX Stock Option Award $0 +42.1K $0.00 42.1K Nov 3, 2022 Common Stock 42.1K $5.08 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 103,008 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,036 shares on November 18, 2022 and January 18, 2023, 1,037 shares on December 18, 2022 and February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F2 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F3 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.
F4 The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price.